PMID- 29062235
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 10
DP  - 2017
TI  - Real-world experience of everolimus as second-line treatment in metastatic renal 
      cell cancer after failure of pazopanib.
PG  - 4885-4893
LID - 10.2147/OTT.S141260 [doi]
AB  - AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell 
      carcinoma (mRCC) patients treated with everolimus as second-line treatment after 
      failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical 
      charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All 
      patients had received or were continuing to receive second-line everolimus 
      treatment after failure of first-line treatment with pazopanib. No other previous 
      therapies were allowed. The primary end point was the determination of 
      progression-free survival (PFS). RESULTS: In total, 31 patients were enrolled. Of 
      these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial 
      Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone 
      prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37-5.06 months). Median 
      overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 
      6.47-13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 
      10.54-19.08 months). Furthermore, 32% of patients temporarily discontinued 
      everolimus due to adverse events (AEs), and 22% of patients discontinued 
      everolimus permanently due to toxicity. Most common toxicities were anemia (29%), 
      stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) 
      were graded as 3 or 4 and were reported by 13 patients (42%). CONCLUSION: This 
      study provides data exclusively on the sequence pazopanib-everolimus in mRCC. 
      Everolimus has a favorable safety profile and is active. The short PFS and OS 
      could be attributed to the fact that the pazopanib-everolimus sequence was mainly 
      offered to patients with adverse prognostic features, resulting in a modest 
      increase in the combined OS of our population.
FAU - Koutsoukos, Konstantinos
AU  - Koutsoukos K
AD  - Hellenic Genito-Urinary Cancer Group.
AD  - Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, National 
      and Kapodistrian University of Athens, Athens, Greece.
FAU - Bamias, Aristotelis
AU  - Bamias A
AD  - Hellenic Genito-Urinary Cancer Group.
AD  - Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, National 
      and Kapodistrian University of Athens, Athens, Greece.
FAU - Tzannis, Kimon
AU  - Tzannis K
AD  - Hellenic Genito-Urinary Cancer Group.
FAU - Espinosa Montano, Marta
AU  - Espinosa Montano M
AD  - Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, 
      Spain.
FAU - Bozionelou, Vasiliki
AU  - Bozionelou V
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion.
FAU - Christodoulou, Christos
AU  - Christodoulou C
AD  - 2nd Oncology Clinic, Metropolitan Hospital, Piraeus.
FAU - Stefanou, Dimitra
AU  - Stefanou D
AD  - 1st Department of Medical Oncology, Saint Savvas Anticancer Hospital, Athens.
FAU - Kalofonos, Haralabos
AU  - Kalofonos H
AD  - Division of Oncology, Department of Medicine, University Hospital, University of 
      Patras Medical School, Patras.
FAU - Duran, Ignacio
AU  - Duran I
AD  - Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, 
      Spain.
FAU - Papazisis, Konstantinos
AU  - Papazisis K
AD  - Hellenic Genito-Urinary Cancer Group.
AD  - Euromedica General Clinic, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
DEP - 20171006
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5640393
OTO - NOTNLM
OT  - everolimus
OT  - pazopanib
OT  - renal cell carcinoma
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:01
PMCR- 2017/10/06
CRDT- 2017/10/25 06:00
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:01 [medline]
PHST- 2017/10/06 00:00 [pmc-release]
AID - ott-10-4885 [pii]
AID - 10.2147/OTT.S141260 [doi]
PST - epublish
SO  - Onco Targets Ther. 2017 Oct 6;10:4885-4893. doi: 10.2147/OTT.S141260. eCollection 
      2017.